Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Tscan Therapeutics Inc(TCRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TCRX
10/02/2026: TCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Tscan Therapeutics is a clinical-stage biotechnology company developing TCR-engineered T cell therapies to treat various cancers. The company's main strength lies in its proprietary TCR-TAP discovery platform, which enables it to identify novel therapeutic targets. Its investment story centers on the potential for its clinical-stage assets, such as TSC-100, to offer new treatments for leukemia. However, the company faces high risks, including the absence of revenue, significant cash burn, and intense competition from well-capitalized pharmaceutical giants. This stock is best suited for high-risk growth investors; key developments to monitor include upcoming clinical trial data and any potential strategic partnerships.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth opportunity dependent on the clinical success of pipeline assets. |
| Momentum investor | Weak fit | Momentum status is conditional on positive clinical data or market uptake, which is currently unproven. |
| Value investor | Weak fit | The company is pre-revenue with significant cash burn, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Tscan is a clinical-stage biotech and does not pay a dividend. |
| Low-risk investor | Weak fit | Biotechnology R&D carries extreme volatility and capital risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are extremely sensitive to trial news and regulatory updates. |
| Valuation risk | High | Valuations are speculative as they depend on the uncertain success of future pipeline assets. |
| Competition risk (Biopharma) | High | Major, well-funded competitors can outspend and outmaneuver smaller developers. |
| Business quality | Medium | The company relies on a proprietary platform, but business quality is limited by the lack of revenue. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Failure at any clinical stage could compromise the entire business model. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -69.86% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.52M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1.0M shares | Beta 1.07 | 52 Weeks Range 0.29 - 2.57 | Updated Date 10/02/2026 |
52 Weeks Range 0.29 - 2.57 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Clinical trial development and licensing of TCR-T cell therapies. | The company currently does not generate sales and burns cash to fund the development of its cancer drugs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15.42M | Price to Sales(TTM) 3.03 |
Enterprise Value 15.42M | Price to Sales(TTM) 3.03 | ||
Enterprise Value to Revenue 2.17 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 63.50M | Shares Floating 54.37M |
Shares Outstanding 63.50M | Shares Floating 54.37M | ||
Percent Insiders 0.19 | Percent Institutions 67.87 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tscan Therapeutics Inc
Exchange NASDAQ | Headquarters Waltham, MA, United States | ||
IPO Launch date 2021-07-16 | CEO, Principal Financial Officer, Principal Accounting Officer & Director Dr. Gavin MacBeath Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 138 | Website https://www.tscan.com |
Full time employees 138 | Website https://www.tscan.com | ||
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.